Liabilities / Assets
12th percentile
Tied with the lowest-debt nonprofits in its peer group.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.00x
Liabilities / Revenue
11th percentile
Tied with the lowest-debt nonprofits in its peer group.
Net Margin
52nd percentile
Higher net margin than 52% of similar nonprofits.
Top Officer Pay
47th percentile
Higher top officer pay than 47% of similar nonprofits.
Top officer pay equals 4.9% of source-year revenue.
Asset Growth
55th percentile
Faster asset growth than 55% of similar nonprofits.
Revenue Growth
88th percentile
Faster revenue growth than 88% of similar nonprofits.
Balance Sheet
Assets
Up$70,845,903
Up $383,117 (+0.5%) from 2021
Net Assets
Up$70,845,903
Up $383,117 (+0.5%) from 2021
Liabilities
Flat$0
Flat from 2021
Revenue And Expenses
Revenue
Up$5,241,349
Up $1,794,585 (+52%) from 2021
Expenses
Up$4,859,232
Up $776,669 (+19%) from 2021
Net Income
Up$382,117
Up $1,017,916 (+160%) from 2021
Historical Trend
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2022 to Dec 31, 2022
- Signed
- Nov 7, 2023
- Return Version
- 2022v5.0
Compensation and Service Providers
Employees
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| Jeff Polak | Dir, Pres, Executive Director | FT | $247,768 | $11,000 | $258,768 |
| David Polak | Director | - | $0 | - | - |
| Janet Polak | Director | - | $0 | - | - |
| Robert Polak | Director | - | $0 | - | - |
| Jonathan Seltzer | Director | - | $0 | - | - |
Grants and Assistance
Foundation Grants and Related Investments
| Type | Recipient | Purpose | Status | Location | Amount |
|---|---|---|---|---|---|
| Paid Grant | AMERICANS FOR BEN-GURION UNIVERSITY INC | Israel's National Artificial Intelligence Resilience Laboratory | PC | NEW YORK, NY, US | $800,000 |
| Paid Grant | ISRAEL EMERGENCY ALLIANCE - STANDWITHUS | General & Unrestricted | PC | LOS ANGELES, CA, US | $200,000 |
| Paid Grant | JEWISH FEDERATION COUNCIL OF GREATER LOS ANGELES | General & Unrestricted | PC | LOS ANGELES, CA, US | $140,000 |
| Paid Grant | CEDARS-SINAI MEDICAL CENTER | Board of Governors Innovation Center | PC | W HOLLYWOOD, CA, US | $100,000 |
| Paid Grant | FRIENDS OF ELNET | General & Unrestricted | PC | SKOKIE, IL, US | $100,000 |
| Paid Grant | THE JEWISH INSTITUTE FOR NATIONAL SECURITY OF AMER | General & Unrestricted | PC | WASHINGTON, DC, US | $100,000 |
| Paid Grant | JEWISH FEDERATION COUNCIL OF GREATER LOS ANGELES | expanding the Community Security Initiative (CSI) through the new CSI Public Outreach Program | PC | LOS ANGELES, CA, US | $75,000 |
| Paid Grant | TRIBE MEDIA CORP | General & Unrestricted | PC | LOS ANGELES, CA, US | $75,000 |
| Paid Grant | SIMON WIESENTHAL CENTER INC | Moriah Films' comprehensive documentary about the life and legacy of David Ben-Gurion | PC | LOS ANGELES, CA, US | $70,000 |
| Paid Grant | FRIENDS OF THE ISRAEL DEFENSE FORCES - LOS ANGELES | sponsor 13 additional IMPACT! Scholarship students | PC | LOS ANGELES, CA, US | $52,000 |
| Paid Grant | MOISHE HOUSE | funds for Sherman Oaks and the other LA Moishe Houses | PC | ENCINITAS, CA, US | $50,000 |
| Paid Grant | PRAGER UNIVERSITY FOUNDATION | General & Unrestricted | PC | SHERMAN OAKS, CA, US | $50,000 |
| Paid Grant | REPORT INC - RESEARCH EVALUATION PROMOTING OR | General & Unrestricted | PC | SPRING HOUSE, PA, US | $50,000 |
| Paid Grant | UNIVERSITY OF SOUTHERN CALIFORNIA | Furthering the mission of the "USC Center for the Political Future" | PC | LOS ANGELES, CA, US | $50,000 |
| Paid Grant | ISRAEL CANCER RESEARCH FUND INC | Research Career Development Program | PC | NEW YORK, NY, US | $49,500 |
| Paid Grant | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | MISTI MIT-Israel fund to support student internships | PC | CAMBRIDGE, MA, US | $40,000 |
| Paid Grant | MIDDLE EAST FORUM | to fund approximately 10 percent of annual Israel Victory Project | PC | PHILADELPHIA, PA, US | $40,000 |
| Paid Grant | CENTRAL FUND OF ISRAEL | General & Unrestricted | PC | CEDARHURST, NY, US | $35,000 |
| Paid Grant | AYN RAND INSTITUTE THE CENTER FOR THE ADVANCEMENT | General & Unrestricted | PC | SANTA ANA, CA, US | $30,000 |
| Paid Grant | AYN RAND INSTITUTE THE CENTER FOR THE ADVANCEMENT | Free Books Program for Teachers in Los Angeles County | PC | SANTA ANA, CA, US | $25,000 |
| Paid Grant | CEDARS-SINAI MEDICAL CENTER | General & Unrestricted | PC | W HOLLYWOOD, CA, US | $25,000 |
| Paid Grant | IMAGINATION PRODUCTIONS INC | Initial research phase for film project | PC | SUNRISE, FL, US | $25,000 |
| Paid Grant | LAWFARE PROJECT INC | General & Unrestricted | PC | NEW YORK, NY, US | $25,000 |
| Paid Grant | LOS ANGELES JEWISH HOME FOR THE AGING | General & Unrestricted | PC | RESEDA, CA, US | $25,000 |
| Paid Grant | TURNING POINT USA INC | Jewish Programs in the 2022-2023 academic year | PC | PHOENIX, AZ, US | $25,000 |
| Paid Grant | YOUNG AMERICA'S FOUNDATION | to sponsor 10 students to our 2023 High School conferences at the Reagan Ranch | PC | RESTON, VA, US | $25,000 |
| Paid Grant | AMCHA INITIATIVE | General & Unrestricted | PC | SANTA CRUZ, CA, US | $20,000 |
| Paid Grant | COMMITTEE FOR ACCURACY IN MIDDLE EAST REPORTING IN | General & Unrestricted | PC | BOSTON, MA, US | $20,000 |
| Paid Grant | ENDOWMENT FOR MIDDLE EAST TRUTH | General & Unrestricted | PC | SILVER SPRING, MD, US | $20,000 |
| Paid Grant | PROCLAIMING JUSTICE TO THE NATIONS INC | General & Unrestricted | PC | FRANKLIN, TN, US | $20,000 |
| Paid Grant | JEWISH FEDERATION COUNCIL OF GREATER LOS ANGELES | PJ Library fund in Los Angeles | PC | LOS ANGELES, CA, US | $18,000 |
| Paid Grant | AMERICAN FRIENDS OF ISRAELI NAVY SEALS INC | funds for Three scholarships each be "repaid" with 120 hours of community service to impactful partner organizations;(800 NIS) Passover gift vouchers for Israel Navy SEAL unit soldiers in financial need | PC | NEW YORK, NY, US | $15,100 |
| Paid Grant | DAVID HOROWITZ FREEDOM CENTER | General & Unrestricted | PC | VALENCIA, CA, US | $15,000 |
| Paid Grant | HAROLD GRINSPOON FOUNDATION | PJ Library fund | SO I | AGAWAM, MA, US | $15,000 |
| Paid Grant | AMERICAN FRIENDS OF SHEBA MEDICAL CENTER INC | General & Unrestricted | PC | LOS ANGELES, CA, US | $10,000 |
| Paid Grant | AMERICAN FRIENDS OF THE ISRAEL PHILHARMONIC ORCHES | General & Unrestricted | PC | LOS ANGELES, CA, US | $10,000 |
| Paid Grant | AMERICAN SOCIETY FOR TECHNION- ISRAEL INSTITUTE OF | General & Unrestricted | PC | NEW YORK, NY, US | $10,000 |
| Paid Grant | BUCKLEY SCHOOL | General & Unrestricted | PC | SHERMAN OAKS, CA, US | $10,000 |
| Paid Grant | CROHN'S & COLITIS FOUNDATION OF AMERICA - THE GREA | General & Unrestricted | PC | LOS ANGELES, CA, US | $10,000 |
| Paid Grant | CUFI CHURCH ASSOCIATION | General & Unrestricted | PC | SAN ANTONIO, TX, US | $10,000 |
| Paid Grant | HILLSDALE COLLEGE | General & Unrestricted | PC | HILLSDALE, MI, US | $10,000 |
| Paid Grant | HONEST REPORTING COM INC | General & Unrestricted | PC | NEW YORK, NY, US | $10,000 |
| Paid Grant | IMAGINATION PRODUCTIONS INC | General & Unrestricted | PC | SUNRISE, FL, US | $10,000 |
| Paid Grant | JEWISH NEWS SERVICE INC | General & Unrestricted | PC | NEWTON, MA, US | $10,000 |
| Paid Grant | CONCERN FOUNDATION | General & Unrestricted | PC | LOS ANGELES, CA, US | $6,000 |
| Paid Grant | AMERICAN FRIENDS OF THE ISRAEL MUSEUM | General & Unrestricted | PC | NEW YORK, NY, US | $5,000 |
| Paid Grant | AMERICAN YOUTH SYMPHONY INC | General & Unrestricted | PC | EL SEGUNDO, CA, US | $5,000 |
| Paid Grant | BEIT TSHUVAH | General & Unrestricted | PC | LOS ANGELES, CA, US | $5,000 |
| Paid Grant | FOUNDATION FOR ECONOMIC EDUCATION INC | General & Unrestricted | PC | ATLANTA, GA, US | $5,000 |
| Paid Grant | FOUNDATION FOR INDIVIDUAL RIGHTS AND EXPRESSION IN | General & Unrestricted | PC | PHILADELPHIA, PA, US | $5,000 |
| Paid Grant | FRIENDS OF ISRAEL SCI-TECH SCHOOLS INC | General & Unrestricted | PC | NEW YORK, NY, US | $5,000 |
| Paid Grant | IMERMAN ANGELS | General & Unrestricted | PC | CHICAGO, IL, US | $5,000 |
| Paid Grant | ISRAEL TENNIS CENTERS FOUNDATION INC | General & Unrestricted | PC | NEW YORK, NY, US | $5,000 |
| Paid Grant | JEWBELONG INC | General & Unrestricted | PC | VERONA, NJ, US | $5,000 |
| Paid Grant | LOS ANGELES PHILHARMONIC ASSOCIATION | General & Unrestricted | PC | LOS ANGELES, CA, US | $5,000 |
| Paid Grant | LOS ANGELES SHERIFFS FOUNDATION | General & Unrestricted | PC | LOS ANGELES, CA, US | $5,000 |
| Paid Grant | MANHATTAN INSTITUTE FOR POLICY RESEARCH INC | General & Unrestricted | PC | NEW YORK, NY, US | $5,000 |
| Paid Grant | MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC | General & Unrestricted | PC | WASHINGTON, DC, US | $5,000 |
| Paid Grant | MUSEUM ASSOCIATES | General & Unrestricted | PC | LOS ANGELES, CA, US | $5,000 |
| Paid Grant | PACIFIC LEGAL FOUNDATION | General & Unrestricted | PC | SACRAMENTO, CA, US | $5,000 |
| Paid Grant | PARDES INSTITUTE OF JEWISH STUDIES NORTH AMERICA I | General & Unrestricted | PC | NEW YORK, NY, US | $5,000 |
| Paid Grant | ROAD RUNNERS CLUB OF AMERICA | Track Permits program | PC | LOS ANGELES, CA, US | $5,000 |
| Paid Grant | STUDENTS RUN AMERICA | General & Unrestricted | PC | TARZANA, CA, US | $5,000 |
| Paid Grant | THE MAPLE COUNSELING CENTER | General & Unrestricted | PC | BEVERLY HILLS, CA, US | $5,000 |
| Paid Grant | THE OPEN TEMPLE | General & Unrestricted | PC | VENICE, CA, US | $5,000 |
| Paid Grant | UNITED STATES HOLOCAUST MEMORIAL MUSEUM | General & Unrestricted | PC | WASHINGTON, DC, US | $5,000 |
| Paid Grant | WASHINGTON INSTITUTE FOR NEAR EAST POLICY | General & Unrestricted | PC | WASHINGTON, DC, US | $5,000 |
| Paid Grant | JEWISH FUNDERS NETWORK | General & Unrestricted | PC | NEW YORK, NY, US | $3,600 |
| Paid Grant | REMEMBER US THE HOLOCAUST BNAI MITZVAH PROJECT | General & Unrestricted | PC | SANTA MONICA, CA, US | $3,600 |
| Paid Grant | AMERICANS FOR BEN-GURION UNIVERSITY INC | General & Unrestricted | PC | NEW YORK, NY, US | $2,500 |
| Paid Grant | JEWISH WOMENS THEATRE | General & Unrestricted | PC | SANTA MONICA, CA, US | $2,500 |
| Paid Grant | BAYIT SHELANU SYNAGOGUE | General & Unrestricted | PC | LOS ANGELES, CA, US | $1,800 |
Filing and Contact Details
Filer
- Filer Name
- David & Janet Polak Foundation
- EIN
- 45-4797578
- In Care Of
- % Foundation Source
- Phone
- 8008391754
- Address
- Foundation Source 501 Silverside Rd, Wilmington, DE 19809-1377
Signing Officer
- Name
- Jeffrey Polak
- Title
- President
- Phone
- 8008391754
- Signed
- 2023-11-07
- Discuss with paid preparer
- Yes
Preparer
- Firm
- Foundation Source
- Address
- 3333 New Hyde Park Rd Ste 406, New Hyde Park, NY 11042
- Preparer
- Jeffrey D Haskell
- Phone
- 8008391754
Raw XML AppendixShowing 400 of 1,819 raw XML fields
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| CompensationExplanation/CompensationExplanationGrp/PersonNm | 0 | Jeff Polak |
| CompensationExplanation/CompensationExplanationGrp/ShortExplanationTxt | 0 | * DAVID POLAK (DIRECTOR), JANET POLAK (DIRECTOR) AND JEFF POLAK PRESIDENT/DIRECTOR/EXECUTIVE DIRECTOR), OF DAVID & JANET POLAK FOUNDATION (THE "FOUNDATION"), ARE PRINCIPALS AT THE INVESTMENT MANAGEMENT FIRM POLAK INVESTORS, LLC, A DISQUALIFIED PERSON WHICH PROVIDES INVESTMENT MANAGEMENT SERVICES TO THE FOUNDATION. IN THE TAXABLE YEAR ENDING DECEMBER 31, 2022, THE FOUNDATION PAID $394,893 FOR INVESTMENT MANAGEMENT SERVICES RENDERED BY SUCH DISQUALIFIED PERSON, AS REPORTED IN PART I, LINE 16C. THE REASONABLENESS OF THE PROFESSIONAL FEES WAS ESTABLISHED BY AN OUTSIDE COMPENSATION COMMITTEE, WHICH REVIEWED THE RATES CHARGED BY COMPARABLE INVESTMENT MANAGEMENT FIRMS. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 0 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 1 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 2 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 3 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 4 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 5 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 6 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 7 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 8 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 9 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 10 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 11 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 12 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 13 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 14 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 15 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 16 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt | 17 | NO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 0 | NEUROVISION IMAGING INC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 1 | BRUIN BIOMETRICS LLC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 2 | BIOP MEDICAL LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 3 | ONLINE DISRUPTIVE TECHNOLOGIES INC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 4 | ORGENESIS LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 5 | BRYN PHARMA LLC FKA EPI-NOW LLC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 6 | CYWAT TECHNOLOGIES LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 7 | BIO-ACTIVES SYNERYGIO LTD FKA YB MO CHO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 8 | BIO-ACTIVES SYNERYGIO LTD FKA YB MO CHO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 9 | MAXQ AI LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 10 | EXTHERA MEDICAL CORPORATION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 11 | YONALINK LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 12 | AMICROBE INC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 13 | OCTHEALTH LLC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 14 | BIO-ACTIVES SYNERGIO LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 15 | CYWAT TECHNOLOGIES LTD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 16 | NEUROVISION IMAGING INC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt | 17 | YAMO PHARMACEUTICALS LLC |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 0 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 1 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 2 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 3 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 4 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 5 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 6 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 7 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 8 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 9 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 10 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 11 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 12 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 13 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 14 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 15 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt | 16 | See General Explanation for Report Dates |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 0 | 10 Ohaliav St |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 1 | MATAM ADV TECH PK BLD 23 POBX 15050 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 2 | ARAD STREET 9 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 3 | 168 JABOTINSKY ST |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 4 | HITECH VIL 4/9 GIVAT RAM POB 39231 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 5 | HITECH VIL 4/9 GIVAT RAM POB 39231 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 6 | 96 YIGAL ALON STREET ENTRANCE A |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 7 | HADASSAH EIN KEREM HOSP POB 12000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 8 | HI-TECH VILLAGE UNIT 4/9 POB39231 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt | 9 | 168 JABOTINSKY ST |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 0 | RAMAT GAN |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 1 | HAIFA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 2 | TEL AVIV |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 3 | BNEI BRAK |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 4 | JERUSALEM |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 5 | JERUSALEM |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 6 | TEL AVIV |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 7 | JERUSALEM |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 8 | GIVAT RAM |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm | 9 | BNEI BRAK |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 0 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 1 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 2 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 3 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 4 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 5 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 6 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 7 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 8 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd | 9 | IS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 0 | 5252263 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 1 | 3190501 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 2 | 9129102 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 3 | 9129102 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 4 | 6789140 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 5 | 9112001 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd | 6 | 9129102 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 0 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 1 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 2 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 3 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 4 | 305498 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 5 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 6 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 7 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 8 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 9 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 10 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 11 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 12 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 13 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 14 | 100000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 15 | 100000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 16 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt | 17 | 250000 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 0 | 2014-12-17 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 1 | 2015-05-13 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 2 | 2017-04-21 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 3 | 2017-04-21 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 4 | 2017-04-21 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 5 | 2018-07-13 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 6 | 2018-11-26 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 7 | 2018-04-20 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 8 | 2018-07-19 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 9 | 2019-03-19 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 10 | 2019-12-19 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 11 | 2019-11-12 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 12 | 2019-10-31 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 13 | 2021-06-08 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 14 | 2021-10-12 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 15 | 2021-06-15 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 16 | 2022-06-17 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt | 17 | 2022-07-13 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 0 | PRI INVEST-SEE GEN EXPLAN FOR PURPOSE & ADDTL DETAILS RE AMT, AMT EXPENDED, & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 1 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 2 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 3 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 4 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 5 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 6 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 7 | PRI LOAN-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 8 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 9 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 10 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 11 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 12 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 13 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 14 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 15 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 16 | PRI LOAN-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt | 17 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 0 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 1 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 2 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 3 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 4 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 5 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 6 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 7 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 8 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 9 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 10 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 11 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 12 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 13 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 14 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 15 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 16 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt | 17 | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 0 | 1395 GARDEN HIGHWAY SUITE 250 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 1 | 10960 WILSHIRE BLVD SUITE 950 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 2 | 518 NORTH HILLCREST ROAD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 3 | 757 ARNOLD DRIVE SUITE B |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 4 | 3142 TIGER RUN COURT 103 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 5 | 1395 GARDEN HIGHWAY SUITE 250 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 6 | 1395 Garden Highway Suite 250 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt | 7 | 400 Madison Ave Ste 11A |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 0 | SACRAMENTO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 1 | LOS ANGELES |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 2 | BEVERLY HILLS |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 3 | MARTINEZ |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 4 | CARLSBAD |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 5 | SACRAMENTO |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 6 | sacramento |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm | 7 | NEW YORK |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 0 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 1 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 2 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 3 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 4 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 5 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 6 | CA |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd | 7 | NY |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 0 | 95833 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 1 | 90024 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 2 | 90210 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 3 | 94553 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 4 | 92010 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 5 | 95833 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 6 | 95833 |
| ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd | 7 | 10017 |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 0 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 1 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 2 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 3 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 4 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 5 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 6 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 7 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 8 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/FormAndLineReferenceDesc | 9 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 0 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 1 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 2 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 3 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 4 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 5 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 6 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 7 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 8 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/IdentifierTxt | 9 | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 0 | PRI RECIPIENT: NEUROVISION IMAGING, INC. DATES AND AMOUNTS OF PRI: 12/17/2014 $250,000 5/17/2018 $37,502 PURPOSE OF PRI: RESEARCH AND DEVELOPMENT OF DIAGNOSTIC TOOLS FOR EARLY-STAGE DETECTION OF ALZHEIMER'S DISEASE AND OTHER DEGENERATIVE NEUROLOGICAL DISORDERS. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED FULL AND COMPLETE FINANCIAL REPORTS OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 3/25/2015 FOR FYE 12/31/2014 DATE OF REPORT: 5/18/2016 FOR FYE 12/31/2015 DATE OF REPORT: 6/7/2017 FOR FYE 12/31/2016 DATE OF REPORT: 5/11/2018 FOR FYE 12/31/2017 DATE OF REPORT: 11/1/2019 FOR FYE 12/31/2018 DATE OF REPORT: 6/2/2020 FOR FYE 12/31/2019 DATE OF REPORT: 6/28/2021 FOR FYE 12/31/2020 DATE OF REPORT: 8/25/2023 FOR FYE 12/31/2021 DATE OF REPORT: 8/25/2023 FOR FYE 12/31/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 1 | PRI RECIPIENT: BRUIN BIOMETRICS, LLC DATE AND AMOUNT OF PRI: 5/13/2015 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY EARLY-STAGE PRESSURE ULCERS DURING THEIR HOSPITAL STAYS AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORTS OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 5/24/2016 FOR FYE 12/31/2015 DATE OF REPORT: 6/29/2017 FOR FYE 12/31/2016 DATE OF REPORT: 5/15/2018 FOR FYE 12/31/2017 DATE OF REPORT: 6/14/2019 FOR FYE 12/31/2018 DATE OF REPORT: 4/22/2020 FOR FYE 12/31/2019 DATE OF REPORT: 8/25/2022 FOR FYE 12/31/2020 DATE OF REPORT: 8/11/2022 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 2 | PRI RECIPIENT: BIOP MEDICAL LTD DATES AND AMOUNTS OF PRI: 4/21/2017 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY DISEASE AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 6/4/2018 FOR FYE 12/31/2017 DATE OF REPORT: 2/12/2019 FOR FYE 12/31/2018 DATE OF REPORT: 11/13/2021 FOR FYE 12/31/2019 DATE OF REPORT: 11/13/2021 FOR FYE 12/31/2020 Although the foundation has made multiple attempts to obtain formal reports for 2021 and 2022, it has been unable to do so. However, BIOP has informally indicated that it has neither funds available nor working staff, and that its activities have been reduced to the bare minimum from the onset of the pandemic and have not since recovered. Per Section 53.4945-5(e)(2) of the Treasury Regulations, the failure of PRI Recipient to submit an annual report will not result in a taxable expenditure for the Foundation because the Foundation (i) made the grant in accordance with paragraph (b) of said section of the Regulations, (ii) has complied with the reporting requirements contained in paragraph (d) of said section of the Regulations, (iii) made a reasonable effort to obtain the required report, and (iv) will withhold all future payments on any grant to this grantee until such report is furnished. THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 3 | PRI RECIPIENT: ONLINE DISRUPTIVE TECHNOLOGIES, INC. DATE AND AMOUNT OF PRI: 4/21/2017 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY CANCER AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 6/6/2018 FOR FYE 12/31/2017 DATE OF REPORT: 2/12/2019 FOR FYE 12/31/2018 DATE OF REPORT: 6/1/2020 FOR FYE 12/31/2019 DATE OF REPORT: 8/18/2021 FOR FYE 12/31/2020 DATE OF REPORT: 3/20/2023 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 4 | PRI RECIPIENT: BRYN PHARMA LLC F/K/A EPI-NOW LLC DATE AND AMOUNT OF PRI: 7/13/2018 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH OF THOSE WHO REQUIRE EPINEPHRINE AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 8/23/2019 FOR FYE 12/31/2018 DATE OF REPORT: 10/24/2020 FOR FYE 12/31/2019 DATE OF REPORT: 8/2/2021 FOR FYE 12/21/2020 DATE OF REPORT: 5/16/2023 FOR FYE 12/21/2021 DATE OF REPORT: 4/25/2023 FOR FYE 12/21/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. APPRECIATION OF PROPERTY. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 5 | PRI RECIPIENT: ORGENESIS LTD. DATE AND AMOUNT OF PRI: 4/21/2017 $305,498 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY DIABETES BY WAY OF RESEARCHING AND BRINGING TO CLINICAL TRIAL THE COMPANY TECHNOLOGY SOLUTION. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED FULL AND COMPLETE FINANCIAL REPORTS OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 9/9/2018 FOR FYE 12/31/2017 DATE OF REPORT: 10/20/2020 FOR FYE 12/31/2018 DATE OF REPORT: 10/20/2020 FOR FYE 12/31/2019 DATE OF REPORT: 5/20/2021 FOR FYE 12/31/2020 DATE OF REPORT: 5/14/2023 FOR FYE 12/31/2021 DATE OF REPORT: 5/14/2023 FOR FYE 12/31/2022 THE FOUNDATION EXERCISED AN OPTION TO EXCHANGE ITS INTEREST IN THE INVESTEE FOR THE STOCK IN THE PARENT COMPANY OF THE INVESTED. THIS WAS DONE TO PRESERVE THE PRI AND NOT TO GENERATE INCOME OR FOR THE APPRECIATION OF PROPERTY. THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 6 | PRI RECIPIENT: CYWAT TECHNOLOGIES LTD DATES AND AMOUNTS OF PRI: 11/26/2018 $250,000 3/3/2021 $7,101 PURPOSE OF PRI: TO PROMOTE THE HEALTH OF PEOPLE WHO ARE AFFECTED BY POLLUTED DRINKING WATER BY FUNDING THE DEVELOPMENT OF A WATER MONITORING SYSTEM THAT IS DISTRIBUTED THROUGHOUT THE ENTIRE WATER GRID AND WHICH CAN IMMEDIATELY DETECT POTENTIAL DANGERS. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 6/18/2019 FOR FYE 12/31/2018 DATE OF REPORT: 1/13/2020 FOR FYE 12/31/2019 DATE OF REPORT: 1/20/2022 FOR FYE 12/31/2020 DATE OF REPORT: 1/16/2022 FOR FYE 12/31/2021 DATE OF REPORT: 6/13/2023 FOR FYE 12/31/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 7 | PRI RECIPIENT: BIO-ACTIVES SYNERGIO LTD. F/K/A Y&B MOTHERS CHOICE LTD. DATE AND AMOUNT OF PRI: 4/20/2018 $250,000 PURPOSE OF PRI: TO PROMOTE HEALTH BY FUNDING RESEARCH INTO DEVELOPING NON HAZARDOUS, NATURAL PRODUCTS THAT DO NOT ENDANGER HUMAN HEALTH. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2018 DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2019 DATE OF REPORT: 11/13/2022 FOR FYE 12/31/2020 DATE OF REPORT: 9/18/2023 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 8 | PRI RECIPIENT: BIO-ACTIVES SYNERGIO LTD. F/K/A Y&B MOTHERS CHOICE LTD. DATE AND AMOUNT OF PRI: 7/19/2018 $250,000 PURPOSE OF PRI: TO PROMOTE HEALTH BY FUNDING RESEARCH INTO DEVELOPING NON HAZARDOUS, NATURAL PRODUCTS THAT DO NOT ENDANGER HUMAN HEALTH. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2018 DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2019 DATE OF REPORT: 11/13/2022 FOR FYE 12/31/2020 DATE OF REPORT: 9/18/2023 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| GeneralExplanationAttachment/GeneralExplanationGrp/MediumExplanationTxt | 9 | PRI RECIPIENT: MAXQ AI, LTD DATE OF PRI: 3/19/2019 $250,000 PURPOSE OF PRI: TO PROMOTE THE DEVELOPMENT OF A PRODUCT THAT WILL SUBSTANTIALLY BENEFIT THE PUBLIC BY INCORPORATING SOPHISTICATED ARTIFICIAL INTELLIGENCE INTO DIAGNOSTIC RADIOLOGY. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 10/13/2020 FOR FYE 12/31/2019 DATE OF REPORT: 7/20/2021 FOR FYE 12/31/2020 DATE OF REPORT: 3/24/2023 FOR FYE 12/31/2021 DATE OF REPORT: 7/7/2023 FOR FYE 12/31/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| InvestmentsCorpBondsSchedule/InvestmentsCorporateBondsGrp/BondNm | 0 | EDISON INTL BOND PERPETUAL - 5 |
| InvestmentsCorpBondsSchedule/InvestmentsCorporateBondsGrp/EOYBookValueAmt | 0 | 1000149 |
| InvestmentsCorpBondsSchedule/InvestmentsCorporateBondsGrp/EOYFMVAmt | 0 | 818390 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 0 | 735250 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 1 | 263446 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 2 | 84323 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 3 | 76117 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 4 | 150587 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 5 | 757500 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 6 | 198370 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 7 | 274208 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 8 | 19368 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 9 | 102249 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 10 | 19784 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 11 | 88332 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 12 | 134168 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 13 | 262699 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 14 | 248049 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 15 | 94101 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 16 | 82086 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 17 | 139670 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 18 | 177409 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 19 | 136767 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 20 | 66822 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 21 | 425563 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 22 | 466000 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 23 | 137340 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 24 | 308509 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 25 | 206264 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 26 | 8731 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 27 | 109720 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 28 | 17953 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 29 | 90356 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 30 | 361740 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 31 | 140581 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 32 | 391515 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 33 | 41828 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 34 | 226736 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 35 | 190621 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 36 | 57245 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 37 | 491587 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 38 | 186121 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 39 | 60260 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 40 | 403984 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 41 | 78926 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 42 | 231728 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 43 | 147503 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 44 | 40705 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 45 | 226844 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 46 | 300822 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 47 | 109012 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 48 | 574088 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 49 | 115963 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 50 | 108485 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 51 | 9760 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 52 | 142250 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 53 | 18170 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 54 | 111551 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 55 | 294452 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 56 | 8916 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 57 | 202042 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 58 | 36513 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 59 | 306123 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 60 | 181332 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 61 | 2013 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 62 | 30848 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 63 | 48470 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 64 | 220170 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 65 | 161969 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt | 66 | 90189 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 0 | 816503 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 1 | 204102 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 2 | 142790 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 3 | 48100 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 4 | 150654 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 5 | 429500 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 6 | 102880 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 7 | 362580 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 8 | 19120 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 9 | 104790 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 10 | 22670 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 11 | 51800 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 12 | 81800 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 13 | 524860 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 14 | 226150 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 15 | 96660 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 16 | 82000 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 17 | 287910 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 18 | 390000 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 19 | 70980 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 20 | 151200 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 21 | 590024 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 22 | 931900 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 23 | 121040 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 24 | 234080 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 25 | 213907 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 26 | 8694 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 27 | 83400 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 28 | 41720 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 29 | 94325 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 30 | 336400 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 31 | 269100 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 32 | 166600 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 33 | 66750 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 34 | 236100 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 35 | 283640 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 36 | 102900 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 37 | 517510 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 38 | 152100 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 39 | 237000 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 40 | 329184 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 41 | 115286 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 42 | 441625 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 43 | 281400 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 44 | 23680 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 45 | 554750 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 46 | 549780 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 47 | 134830 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 48 | 748403 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 49 | 155050 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 50 | 119600 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 51 | 7280 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 52 | 114000 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 53 | 22344 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 54 | 132100 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 55 | 614880 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 56 | 10121 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 57 | 227800 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 58 | 9120 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 59 | 350960 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 60 | 172500 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 61 | 679 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 62 | 43030 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 63 | 50100 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 64 | 1142 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt | 65 | 72134 |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 0 | AGNICO EAGLE MINES LTD |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 1 | AMERICAN AXLE & MFG HOLDINGS I |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 2 | ARCH COAL, INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 3 | ARDAGH METAL PACKAGING SA |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 4 | B2 GOLD CORP COM NPV |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 5 | BARRICK GOLD CORPORATION |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 6 | BAYER A G SPONSORED ADR |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 7 | BERRY PLASTICS GROUP INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 8 | BLOOM ENERGY CORP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 9 | BP PLC SPONSORED ADR |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 10 | CAMECO CORPORATION |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 11 | CENTERRA GOLD INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 12 | CENTURY ALUMINUM COMPANY |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 13 | CHENIERE ENERGY INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 14 | CITIGROUP INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 15 | CLIFFS NATURAL RESOURCES INC. |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 16 | COMPASS MINERALS INTERNATIONAL |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 17 | COMSTOCK RES INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 18 | CONSOL ENERGY, INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 19 | CONSTELLIUM NV |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 20 | COPPER MOUNTAIN MINI NG CORP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 21 | COTERRA ENERGY INC |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 22 | CVS CAREMARK CORP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 23 | DANA HOLDING CP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 24 | ELDORADO GOLD CORP COM NPV |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 25 | ENDEAVOUR MINING CORP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 26 | FIDELITY CONSERV INC BD FD |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 27 | FIRST MAJESTIC SILVER CORP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 28 | FIRST QUANTUM MINERALS LTD |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 29 | FLUTTER ENTERTAINMENT ORD SHS |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 30 | GENERAL MOTORS |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 31 | GOLD FIELDS LTD ADS |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 32 | GRAFTECH INTERNATIONAL LTD |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 33 | GRAPHIC PACKAGING CORP COM STK |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 34 | HALLIBURTON COMPANY |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 35 | HESS CORP |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 36 | HOLCIM LTD SPON ADS |
| InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm | 37 | HOLCIM N |
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2022 • Form 990PFDetailed filing. Detailed filing data is available for this year.
- Assets
- $70,845,903
- Liabilities
- $0
- Net assets
- $70,845,903
- Revenue
- $5,241,349
- Expenses
- $4,859,232
- Net income
- $382,117